A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Conditions
Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Northside Hospital, Atlanta, Georgia, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
University Of Nebraska Medical Center, Omaha, Nebraska, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
Local Institution - 0009, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Local Institution - 0023, Pittsburgh, Pennsylvania, United States
Tennessee Oncology, Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb